acylation stimulating protein
{{Short description|Protein in humans}}
Complement 3 (C3) through its interaction with factors B and D (adipsin) generates C3a. In the human body, C3a is rapidly cleaved by carboxypeptidase B or carbxyopeptidase N, that remove the carboxyl-terminal arginine to generate C3adesArg.{{harvnb |Baldo|Sniderman|St-Luce|Avramoglu|1993| pp=1543–1547}} Thus, most of plasmatic C3a is present in C3adesArg form. C3adesArg is more commonly named ASP or acylation-stimulating-protein due to its marked stimulating action on triacylglycerol synthesis in human adipocytes and skin fibroblasts.{{harvnb |Cianflone|Sniderman|Walsh|Vu1989| pp=426–430}} ASP is also known for its augmentation of glucose transport and inhibiting action on hormone-sensitive lipase. Because of these actions, it is linked to the pathogenesis of obesity,{{harv |Sniderman|Maslowska|Cianflone|2000| pp=291–296}} having been demonstrated to be present at increased levels in patients with obesity,{{harvnb |Maslowska|Vu|Phelis|Sniderman|1999| pp=679–686}} diabetes mellitus type 2{{harvnb |Koistinen|Vidal|Karonen|Dusserre|2001| pp=1034–1039}} and coronary artery disease.{{harvnb |Cianflone|Zhang|Genest Jr|Sniderman|1997| pp=1239–1244}}
ASP lis a ligand for C5L2, a G-protein-coupled receptor.{{harvnb |Cui|Lapointe|Gauvreau|Kalant|2009| pp=3207–3217}}
The view of C3a/C3adesArg as an acylation stimulating activity is not universally accepted. The evidence is discussed in a recent review.{{cite journal |vauthors=Klos A, Wende E, Wareham KJ, Monk PN |title=International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors |journal=Pharmacol. Rev. |volume=65 |issue= 1 |pages= 500–43 |year= 2013 |pmid= 23383423 |doi=10.1124/pr.111.005223|doi-access=free }}
References
{{Reflist}}
Further reading
{{refbegin}}
- {{cite journal |doi=10.1172/JCI116733 |title=The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis |year=1993 |last1=Baldo |first1=A |last2=Sniderman |first2=A D |last3=St-Luce |first3=S |last4=Avramoglu |first4=R K |last5=Maslowska |first5=M |last6=Hoang |first6=B |last7=Monge |first7=J C |last8=Bell |first8=A |last9=Mulay |first9=S |last10=Cianflone |first10=K |journal=Journal of Clinical Investigation |volume=92 |issue=3 |pages=1543–1547 |pmid=8376604 |pmc=288301}}
- {{cite journal |pmid=2909530 |year=1989 |last1=Cianflone |first1=Katherine M. |last2=Sniderman |first2=Allan D. |last3=Walsh |first3=Mark J. |last4=Vu |first4=Hai T. |last5=Gagnon |first5=Jean |last6=Rodriguez |first6=Miguel A. |title=Purification and Characterization of Acylation Stimulating Protein |volume=264 |issue=1 |journal=The Journal of Biological Chemistry |url=http://www.jbc.org/cgi/pmidlookup?view=long&pmid=2909530 |pages=426–30|doi=10.1016/S0021-9258(17)31275-9 |doi-access=free }}
- {{cite journal |last1=Cianflone |first1=K. |last2= Zhang |first2=XJ |last3= Genest Jr |first3=J |last4=Sniderman |first4=A |title=Plasma acylation-stimulating protein in coronary artery disease |journal=Arterioscler Thromb Vasc Biol |date= July 1997 |volume=17|issue=7|pages=1239–44|doi=10.1161/ATVB.17v07.1239 | pmid=9261252|doi-access=free }}
- {{cite journal |first1=Wei |last1=Cui |first2=Marc |last2=Lapointe |first3= Danny |last3=Gauvreau |first4= David |last4=Kalant |first5=Katherine |last5=Cianflone |title= Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation |journal= Mol Immunol |date= October 2009 |volume=46 |issue=16 |pages=3207–17 |doi= 10.1016/j.molimm.2009.08.013 | pmid= 19767107}}
- {{cite journal |doi=10.1097/00041433-200006000-00010 |title=Of mice and men (and women) and the acylation-stimulating protein pathway |year=2000 |last1=Sniderman |first1=Allan D. |last2=Maslowska |first2=Magdalena |last3=Cianflone |first3=Katherine |journal=Current Opinion in Lipidology |volume=11 |issue=3 |pmid=10882345 |pages=291–6}}
- {{cite journal |doi=10.1046/j.1365-2362.1999.00514.x |title=Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations |year=1999 |last1=Maslowska |last2=Vu |last3=Phelis |last4=Sniderman |last5=Rhode |last6=Blank |last7=Cianflone |journal=European Journal of Clinical Investigation |volume=29 |issue=8 |pmid=10457151 |first1=M |first2=H |first3=S |first4=AD |first5=BM |first6=D |first7=K |pages=679–86|s2cid=19694467 }}
- {{cite journal |pmid=11397716 |year=2001 |last1=Koistinen |first1=Heikki A. |last2=Vidal |first2=Hubert |last3=Karonen |first3=Sirkka-Liisa |last4=Dusserre |first4=Eric |last5=Vallier |first5=Paulette |last6=Koivisto |first6=Veikko A. |last7=Ebeling |first7=Pertti |title=Plasma Acylation Stimulating Protein Concentration and Subcutaneous Adipose Tissue C3 mRNA Expression in Nondiabetic and Type 2 Diabetic Men |volume=21 |issue=6 |journal=Arteriosclerosis, Thrombosis, and Vascular Biology |pages=1034–9 |doi=10.1161/01.atv.21.6.1034 |doi-access=free }}
{{refend}}